DENTSPLY SIRONA (XRAY) heads into its upcoming quarterly report with expectations for a year on year revenue decline, as Ariel Investments and Vanguard disclose fresh positions that spotlight institutional interest.

At a share price of US$11.81, DENTSPLY SIRONA has a 1 month share price return of 1.55%. However, a 1 year total shareholder return decline of 11.41% signals that longer term momentum has been weak despite recent institutional interest and product launches.

If this earnings story has you thinking about where else capital could work harder, it may be worth scanning for other healthcare technology ideas through our 33 healthcare AI stocks

With XRAY trading at US$11.81, sitting below analyst targets and screening with a mid range value score, the key question is whether this discount reflects real issues or whether the market is underestimating its potential.

Most Popular Narrative: 74% Undervalued

According to user yiannisz, the most followed narrative on DENTSPLY SIRONA pegs fair value at $45.50 versus the recent $11.81 share price. This implies a large valuation gap that depends on how durable cash flows and profit recovery play out over time.

Dentsply Sirona operates in a corner of healthcare that rarely attracts hype but consistently demands precision. As one of the world’s largest dental equipment and consumables providers, the company sits upstream from patient demand, selling to dental practices rather than consumers. That position shapes everything about its business, from revenue stability to growth expectations.

Want to see what justifies that big gap between price and fair value? This narrative focuses on recurring consumables, long equipment cycles, and a profitability profile that is framed very differently from how the market is currently pricing XRAY.

Result: Fair Value of $45.50 (UNDERVALUED)

However, this depends on XRAY turning a US$598 million loss into sustainable profitability and keeping its 0.8% annual revenue growth from slipping as competition and practice budgets tighten.

Next Steps

If this mix of concern and optimism around XRAY leaves you unsure, take it as a prompt to act promptly and review the data for yourself with the 3 key rewards and 1 important warning sign

Looking for more investment ideas?

If XRAY has sharpened your thinking, do not stop there. Broaden your watchlist with a few focused stock ideas that fit what you are really looking for.

• Target potential mispricings by scanning 49 high quality undervalued stocks that combine lower valuations with solid underlying business metrics.
• Strengthen your income focus by checking 13 dividend fortresses offering higher yields that may appeal if regular cash returns matter to you.
• Prioritise stability by reviewing 72 resilient stocks with low risk scores that score well on resilience and downside protection.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.